IP Library › Granted Patent US 12,377,169
Granted Patent B2
US 12,377,169 · App. 17/916,308 · Granted Aug 5, 2025

Dual AAV-MYO7A vectors with improved safety for the treatment of USH1B

Inventors: Shannon E. Boye (Gainesville, FL); Sanford L. Boye (Gainesville, FL); H. Lee Sweeney (Gainesville, FL); Kaitlyn Calabro (Gainesville, FL)
Assignee: University of Florida Research Foundation, Incorporated
A61K48/005A61K48/0075C07K14/4716C12N15/86A61K38/00C12N2750/14132C12N2750/14143C12N2800/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,377,169
App. No.
17/916,308
Granted
Aug 5, 2025
Kind
B2
Abstract

Disclosed are compositions and methods for treating diseases of the mammalian eye, and in particular, complications of the retina associated with Usher syndrome IB (USH1B). Further disclosed are compositions and methods for treating diseases of the mammalian inner ear, and in particular, complications of ear hair cells associated with Usher syndrome IB (USH1B). The disclosure provides improved AAV-based, dual vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. Described herein are modified hybrid dual vector systems that shift the coding sequence for the MY07A tail domain from the front-half vector to the back-half vector by altering the split point (e.g., from between exons 23 and 24, to between exons 21 and 22), in order to eliminate the production of truncated MY07A protein. Further described herein are improved, codon-modified hybrid and overlap vector systems in which putative stop codons and residual sequences in non-coding sequences are removed.

Claims (19)

1. A polynucleotide vector system comprising:

i) a first AAV vector polynucleotide comprising an inverted terminal repeat at each end of a polynucleotide comprising a promoter followed by a first partial coding sequence that encodes an N-terminal part of a full-length myosin polypeptide, and

ii) a second AAV vector polynucleotide comprising an inverted terminal repeat at each end of a polynucleotide comprising a second partial coding sequence that encodes a C-terminal part of the full-length myosin polypeptide, and

wherein the N-terminal part of the full-length myosin polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 62; and

the C-terminal part of the full-length myosin polypeptide comprises an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 81,

wherein the first partial coding sequence does not encode the single-alpha helix (SAH) domain of the full-length myosin polypeptide, and the first partial coding sequence and the second partial coding sequence encode the full-length myosin polypeptide.

2. The polynucleotide vector system of claim 1 , wherein the promoter is selected from the group consisting of: a CMV promoter, an EF-1 alpha promoter, a cone arrestin promoter, a smCBA promoter, a human myosin 7a gene-derived promoter, a TαC gene-derived promoter, a rhodopsin promoter, a cGMP-phosphodiesterase β-subunit promoter, human or mouse rhodopsin promoter, a hGRK1 promoter, a rod specific IRBP promoter, a VMD2 promoter, a synapsin promoter, a glial fibrillary acidic protein (GFAP) promoter, and combinations thereof.

3. The polynucleotide vector system of claim 1 , comprising a 3′ untranslated region downstream of the second partial coding sequence.

4. The polynucleotide vector system of claim 3 , wherein the 3′ untranslated region comprises a substitution as compared to the wild-type myosin 3′ untranslated region.

5. The polynucleotide vector system of claim 1 , wherein the first AAV vector polynucleotide comprises an overlap sequence and the second AAV vector polynucleotide comprises the overlap sequence, wherein the overlap sequence is an intron of a gene encoding the full-length myosin polypeptide, the AK sequence of the F1 phage, or a synthetic alkaline phosphatase (AP) intron.

6. The polynucleotide vector system of claim 5 , wherein the first AAV vector polynucleotide comprises a splice donor site and the second AAV vector polynucleotide comprises a splice acceptor site.

7. A viral particle comprising the polynucleotide vector system of claim 1 , wherein the viral particle comprises an AAV2, AAV5, AAV7, AAV8, AAV44.9, AAV44.9 (E531D), AAV9-PHP.B, or AAV44.9 (Y733F) capsid.

8. The polynucleotide vector system of claim 1 , wherein the N-terminal part of the full-length myosin polypeptide is at least 95% identical to the amino acid sequence of SEQ ID NO: 62.

9. The polynucleotide vector system of claim 1 , wherein the N-terminal part of the full-length myosin polypeptide consists of amino acid residues 1-862 of SEQ ID NO: 62.

10. The polynucleotide vector system of claim 8 , wherein the C-terminal part of the full-length myosin polypeptide comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 81.

11. The polynucleotide vector system of claim 8 , wherein the C-terminal part of the full-length myosin polypeptide comprises the amino acid sequence of SEQ ID NO: 81.

12. The polynucleotide vector system of claim 11 , wherein the full-length myosin polypeptide is a biologically-active MYO7A polypeptide.

13. The polynucleotide vector system of claim 12 , wherein the promoter is a smCBA promoter.

14. A viral particle comprising the polynucleotide vector system of claim 13 , wherein the viral particle comprises an AAV44.9 (E531D) capsid.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2022
From: BOYE, SHANNON E.; BOYE, SANFORD L.; SWEENEY, H. LEE; CALABRO, KAITLYN
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 062237/0200 →
Continuity (2)
Provisional Application 63003774 · Apr 1, 2020
Related Publication 20230149565A1 · May 18, 2023
References Cited (130)
US 8298818B2 · Boye et al. · 2012 [cited by applicant]
US 10214572B2 · Boye · 2019 [cited by examiner]
US 11325956B2 · Boye et al. · 2022 [cited by applicant]
US 11525139B2 · Simons et al. · 2022 [cited by applicant]
US 11781145B2 · Simons et al. · 2023 [cited by applicant]
US 11807867B2 · Simons et al. · 2023 [cited by applicant]
US 12188041B2 · Dyka et al. · 2025 [cited by applicant]
US 20070161110A1 · Iida et al. · 2007 [cited by applicant]
US 20100003218A1 · Duan et al. · 2010 [cited by applicant]
US 20100266551A1 · Richard et al. · 2010 [cited by applicant]
US 20120003190A1 · Yamoah et al. · 2012 [cited by applicant]
US 20120087862A1 · Hood et al. · 2012 [cited by applicant]
US 20130210895A1 · Boye et al. · 2013 [cited by applicant]
US 20140249208A1 · Bancel et al. · 2014 [cited by applicant]
US 20140256802A1 · Boye et al. · 2014 [cited by applicant]
US 20160022836A1 · Banfi · 2016 [cited by examiner]
US 20160076054A1 · Auricchio et al. · 2016 [cited by applicant]
US 20180015172A1 · Muzyczka et al. · 2018 [cited by applicant]
US 20190002916A1 · Kalatzis et al. · 2019 [cited by applicant]
US 20190153050A1 · Boye et al. · 2019 [cited by applicant]
US 20190309326A1 · Maclaren et al. · 2019 [cited by applicant]
US 20200157573A1 · Boye et al. · 2020 [cited by applicant]
US 20210130421A1 · Boye et al. · 2021 [cited by applicant]
US 20210395778A1 · Dyka et al. · 2021 [cited by applicant]
US 20240011039A1 · Simons et al. · 2024 [cited by applicant]
CA 3034527A1 · 2018 [cited by applicant]
CN 110225975A · 2019 [cited by applicant]
JP 2016516424A · 2016 [cited by applicant]
JP 7240675B2 · 2023 [cited by applicant]
KR 1020070004636A · 2007 [cited by applicant]
WO WO2001070972A2 · 2001 [cited by applicant]
WO WO2008088895A2 · 2008 [cited by applicant]
WO WO2013075008A1 · 2013 [cited by applicant]
WO WO2014140051A1 · 2014 [cited by applicant]
WO WO2014170480A1 · 2014 [cited by examiner]
WO WO2014193716A2 · 2014 [cited by applicant]
WO WO2016131981A1 · 2016 [cited by applicant]
WO WO2016139321A1 · 2016 [cited by applicant]
WO WO2017049252A1 · 2017 [cited by applicant]
WO WO2017100791A1 · 2017 [cited by applicant]
WO WO2017216A1 · 2017 [cited by applicant]
WO WO2018039375A1 · 2018 [cited by applicant]
WO WO2018162748A1 · 2018 [cited by applicant]
WO WO2018204734A1 · 2018 [cited by applicant]
WO WO2019165292A1 · 2019 [cited by applicant]
WO WO2019183641A1 · 2019 [cited by applicant]
WO WO2020148458A1 · 2020 [cited by applicant]
WO WO2021087296A1 · 2021 [cited by applicant]
Calabro. Exploring MYO&A function in novel mouse models and improving AAV-Dual Vector gene therapy for Usher Syndrome 1B. PHD dissertation. University of Florida. pp. 1-138 (Year: 2019). [cited by examiner]
Barnes et al. JACS 2019,141,9004-9017 (Year: 2019). [cited by examiner]
Zhang et al. Nature Communications. 2023. 7534. https://doi.org/10.1038/s41467-023-42747-9. pp. 1-12. [cited by examiner]
Printout from https://www.cff.org/research-clinical-trials/types-cftr-mutations#:˜:text=. Printed 2024. pp. 1-9. [cited by examiner]
[No Author Listed], NCBI Accession No. NM_001632.5. [cited by applicant]
[No Author Listed], NCBI Accession No. NP_001274418. OTOF otoferlin isoform e [ [cited by applicant]
Avraham, What's hot about otoferlin. EMBO J. Dec. 1, 2016;35(23):2502-2504. doi: 10.15252/embj.201695881. Epub Nov. 7, 2016. [cited by applicant]
Gao et al., The Dystrophin Complex: Structure, Function, and Implications for Therapy. Compr Physiol. Jul. 1, 2015;5(3):1223-39. doi: 10.1002/cphy.c140048. Author Manuscript, 33 pages. [cited by applicant]
Geleoc et al., Sound strategies for hearing restoration. Science. May 9, 2014;344(6184):1241062. doi: 10.1126/science.1241062. [cited by applicant]
Hirsch et al., Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors. Methods Mol Biol. 2016;1382:21-39. doi: 10.1007/978-1-4939-3271-9_2. Author Manuscript, 20 pages. [cited by applicant]
Lostal et al., Full-length dystrophin reconstitution with adeno-associated viral vectors. Hum Gene Ther. Jun. 2014:25(6):552-62. doi: 10.1089/hum.2013.210. Epub Mar. 31, 2014. [cited by applicant]
Majewski et al., GT repeats are associated with recombination on human chromosome 22. Genome Res. Aug. 2000;10(8):1108-14. doi: 10.1101/gr.10.8.1108. [cited by applicant]
Pryadkina et al., A comparison of AAV strategies distinguishes overlapping vectors for efficient systemic delivery of the 6.2 kb Dysferlin coding sequence. Mol Ther Methods Clin Dev. Mar. 25, 2015;2:15009. doi: 10.1038/… [cited by applicant]
Yasunaga et al., OTOF encodes multiple long and short isoforms: genetic evidence that the long ones underlie recessive deafness DFNB9. Am J Hum Genet. Sep. 2000;67(3):591-600. doi: 10.1086/303049. Epub Jul. 19, 2000. [cited by applicant]
Akil et al., Restoration of hearing in the VGLUT3 knockout mouse using virally mediated gene therapy. Neuron. Jul. 26, 2012;75(2):283-93. doi: 10.1016/j.neuron.2012.05.019. [cited by applicant]
Extended European Search Report for European Application No. EP 18793935.0 mailed on Feb. 22, 2021. [cited by applicant]
International Search Report and Written Opinion mailed Jul. 30, 2018 for Application No. PCT/US2018/031009. [cited by applicant]
International Preliminary Report on Patentability mailed Nov. 14, 2019 for Application No. PCT/US2018/031009. [cited by applicant]
International Search Report and Written Opinion mailed Feb. 20, 2020 for Application No. PCT/US2019/059549. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/US2019/059549, mailed May 14, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2012/065645 mailed Mar. 29, 2013. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2012/065645 mailed May 30, 2014. [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2021/025281 mailed Jun. 29, 2021. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/025281 mailed Sep. 10, 2021. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/025281 mailed Oct. 13, 2022. [cited by applicant]
Akil et al., Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci U S A. Mar. 5, 2019;116(10):4496-4501. doi: 10.1073/pnas.1817537116. Epub Feb. 19, 2019. [cited by applicant]
Alemi et al., Progress Report: AOS Research Grant: Restoration of Hearing in the Otoferlin Knockout Mouse using Viral Gene Therapy. 145th Annual Meeting. American Otological Society, Inc. Apr. 21-22, 2012; p. 68. Availa… [cited by applicant]
Al-Hussaini et al., Mature retinal pigment epithelium cells are retained in the cell cycle and proliferate in vivo. Mol Vis. 2008;14:1784-91. Epub Oct. 6, 2008. [cited by applicant]
Allocca et al., Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest. May 1, 2008; 118(5): 1955-1964. Published online Apr. 15, 2008. do… [cited by applicant]
Al-Moyed et al., A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. Jan. 2019;11(1):e9396. doi: 10.15252/emmm.201809396. [cited by applicant]
Chen et al., Molecular cloning and domain structure of human myosin-VIIa, the gene product defective in Usher syndrome 1B. Genomics. Sep. 15, 1996;36(3):440-8. doi: 10.1006/geno.1996.0489. [cited by applicant]
Daya et al., Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. Oct. 2008;21(4):583-93. doi: 10.1128/CMR.00008-08. [cited by applicant]
Dong et al., Characterization of genome integrity for oversized recombinant AAV vector. Mol Ther. Jan. 2010;18(1):87-92. doi: 10.1038/mt.2009.258. Epub Nov. 10, 2009. [cited by applicant]
Duan et al., Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. Nov. 1998;72(11):8568-77. [cited by applicant]
Duan et al., Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. Oct. 2001;4(4):383-91. [cited by applicant]
Dyka et al., Dual adeno-associated virus vectors result in efficient in vitro and in vivo expression of an oversized gene, MYO7A. Hum Gene Ther Methods. Apr. 2014;25(2):166-77. doi: 10.1089/hgtb.2013.212. [cited by applicant]
GenBank Submission; NIH/NCBI, Accession No. NP_000251. unconventional myosin-VIIa isoform 1 [ [cited by applicant]
GenBank Submission; NIH/NCBI, Accession No. U39226.1. Human myosin VIIA (USH1B) mRNA, complete cds. Jul. 11, 1996. 5 pages. [cited by applicant]
Ghosh et al., A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. Jan. 2008;16(1):124-30. doi: 10.1038/sj.mt.6300322. Epub Nov. 6, 2007. [cited by applicant]
Ghosh et al., Efficient transgene reconstitution with hybrid dual AAV vectors carrying the minimized bridging sequences. Hum Gene Ther. Jan. 2011;22(1):77-83. doi: 10.1089/hum.2010.122. Epub Dec. 12, 2010. [cited by applicant]
Hashimoto et al., Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B. Gene Therapy. 2007:14;584-594. [cited by applicant]
Jacobson et al., Usher syndromes due to MYO7A, PCDH15, USH2A or GPR98 mutations share retinal disease mechanism. Hum Mol Genet. Aug. 1, 2008;17(15):2405-15. doi: 10.1093/hmg/ddn140. Epub May 7, 2008. [cited by applicant]
Lai et al., Evidence for the Failure of Adeno-associated Virus Serotype 5 to Package a Viral Genome ≥8.2 kb. Mol Ther. 2010; 18 1, 75-79. doi:10.1038/mt.2009.256. [cited by applicant]
Li et al., High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum Gene Ther. Nov. 2010;21(11):1527-43. doi: 10.1089/hum.20… [cited by applicant]
Lopes et al., Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus. Gene Ther. Aug. 2013;20(8):824-33. doi: 10.1038/gt.2013.3. Epub Jan. 24, 2013. Author Manuscript, 21 pages. [cited by applicant]
Petrs-Silva et al., Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther. Feb. 2011;19(2):293-301. doi: 10.1038/mt.2010.234. Epub Nov. 2, 2010. [cited by applicant]
Trapani et al., Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. Feb. 2014;6(2):194-211. doi: 10.1002/emmm.201302948. Epub Dec. 15, 2013. [cited by applicant]
Weil et al., Human myosin VIIA responsible for the Usher 1B syndrome: A predicted membrane-associated motor protein expressed in developing sensory epithelia. Proc Natl Acad Sci U S A. Apr. 16, 1996;93(8):3232-7. doi: 1… [cited by applicant]
Wu et al., Effect of genome size on AAV vector packaging. Mol Ther. Jan. 2010;18(1):80-6. doi: 10.1038/mt.2009.255. Epub Nov. 10, 2009. [cited by applicant]
Yan et al., Inverted terminal repeat sequences are important for intermolecular recombination and circularization of adeno-associated virus genomes. J Virol. Jan. 2005;79(1):364-79. [cited by applicant]
Yan et al., Recombinant AAV-mediated gene delivery using dual vector heterodimerization. Methods Enzymol. 2002;346:334-57. doi: 10.1016/s0076-6879(02)46065-x. [cited by applicant]
Extended European Search Report for European Application No. EP 21781660.2 mailed on Apr. 9, 2024. [cited by applicant]
[No Author Listed] OTOF sequence comparison of Yasunaga SEQ ID No. 70 with present SEQ ID No. 5 (dated Apr. 12, 24), from U.S. Appl. No. 17/290,082 Office Action, filed Apr. 18, 2024, 5 pages. [cited by applicant]
McClements et al., A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts. J Genet Syndr Gene Ther. Nov. 14, 2016;… [cited by applicant]
[No Author Listed] Basics of Sound, the Ear, and Hearing, Hearing Loss: Determining Eligibility for Social Security Benefits. Dobie RA, Van Hemel S, editors. Washington (DC): National Academies Press (US); 2004, p. 42-6… [cited by applicant]
[No Author Listed] Children's Hospital of Philadelphia Performs First Gene Therapy Procedure to Treat Genetic Hearing Loss in United States, American Academy of Audiology, Accessed online: <https://www.audiology.org/chi… [cited by applicant]
[No Author Listed] Genetic Hearing Loss With No Associated Abnormalities, Hereditary Hearing Loss and Its Syndromes, Third Edition. Helga V. Toriello and Shelley D. Smith (Eds.), 2013, p. 164-165 (4 pages). [cited by applicant]
[No Author Listed] GenPept Accession NP _001274418.1, dated Apr. 23, 2017, retrieved from https://www.ncbi.nlm.nih.gov/protein/566559996?sat=46&satkey=73202094, 4 pages. [cited by applicant]
Ahmed et al., Emerging Gene Therapies for Genetic Hearing Loss. J Assoc Res Otolaryngol. Oct. 2017;18(5):649-670. doi: 10.1007/s10162-017-0634-8. Epub Aug. 16, 2017. [cited by applicant]
Akil et al., AAV-Mediated Gene Delivery to the Inner Ear. Methods Mol Biol. 2019;1950:271-282. doi: 10.1007/978-1-4939-9139-6_16. [cited by applicant]
Akil et al., Surgical method for virally mediated gene delivery to the mouse inner ear through the round window membrane. J Vis Exp. Mar. 16, 2015;(97):52187. doi: 10.3791/52187. [cited by applicant]
Hamosh et al., Otoferlin; OTOF, OMIM. (Apr. 2015) Retrieved via The Wayback Machine, URL: <https://web.archive.org/web/20150729163826/http://omim.org/entry/603681>, 8 pages. [cited by applicant]
Holt et al., Split otoferlins reunited. EMBO Mol Med. Jan. 2019;11(1):e9995. doi: 10.15252/emmm.201809995. [cited by applicant]
Kilpatrick et al., Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear. Gene Ther. Jun. 2011;18(6):569-78. doi: 10.1038/gt.2010.175. Epub Jan. 6, 2011. [cited by applicant]
Langouet-Astrie et al., Characterization of intravitreally delivered capsid mutant AAV2-Cre vector to induce tissue-specific mutations in murine retinal ganglion cells. Exp Eye Res. Oct. 2016;151:61-7. doi: 10.1016/j.ex… [cited by applicant]
Li et al., A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization. J Cell Mol Med. Aug. 2017;21(8):1555-1571. doi: 10.1111/jcmm.13086. Epub Mar. 22, 201… [cited by applicant]
Liu et al., Specific and efficient transduction of Cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. Mol Ther. Oct. 2005;12(4):725-33. doi: 10.1016/j.ymthe.2005.03.021. [cited by applicant]
Lopes-Pacheco et al., Self-complementary and tyrosine-mutant rAAV vectors enhance transduction in cystic fibrosis bronchial epithelial cells. Exp Cell Res. Nov. 15, 2018;372(2):99-107. doi: 10.1016/j.yexcr.2018.09.015. … [cited by applicant]
Pangrsic et al., Otoferlin: a multi-C2 domain protein essential for hearing. Trends Neurosci. Nov. 2012;35(11):671-80. doi: 10.1016/j.tins.2012.08.002. Epub Sep. 7, 2012. [cited by applicant]
Petrs-Silva et al., High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther. Mar. 2009;17(3):463-71. doi: 10.1038/mt.2008.269. Epub Dec. 16, 2008. [cited by applicant]
Roux et al., Otoferlin, defective in a human deafness form, is essential for exocytosis at the auditory ribbon synapse. Cell. Oct. 20, 2006;127(2):277-89. doi: 10.1016/j.cell.2006.08.040. [cited by applicant]
Suzuki et al., Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction. Sci Rep. Apr. 3, 2017;7:45524. doi: 10.1038/srep45524. [cited by applicant]
Tao et al., Delivery of Adeno-Associated Virus Vectors in Adult Mammalian Inner-Ear Cell Subtypes Without Auditory Dysfunction. Hum Gene Ther. Apr. 2018;29(4):492-506. doi: 10.1089/hum.2017.120. Epub Jan. 22, 2018. [cited by applicant]
Tertrais et al., Viral Transfer of Mini-Otoferlins Partially Restores the Fast Component of Exocytosis and Uncovers Ultrafast Endocytosis in Auditory Hair Cells of Otoferlin Knock-Out Mice. J Neurosci. May 1, 2019;39(18… [cited by applicant]
Yoshimura et al., Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation. Sci Rep. Feb. 14, 2018;8(1):2980. doi: 10.1038/s41598-018-21233-z. W… [cited by applicant]
Yoshimura et al., Targeted Allele Suppression Prevents Progressive Hearing Loss in the Mature Murine Model of Human TMC1 Deafness. Mol Ther. Mar. 6, 2019;27(3):681-690. doi: 10.1016/j.ymthe.2018.12.014. Epub Jan. 7, 201… [cited by applicant]
Zhang et al., Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success. Front Mol Neurosci. Jun. 26, 2018;11:221. doi: 10.3389/fnmol.2018.00221. [cited by applicant]
Zhang et al., Temperature sensitive auditory neuropathy. Hear Res. May 2016;335:53-63. doi: 10.1016/j.heares.2016.01.008. Epub Jan. 15, 2016. [cited by applicant]
Laine et al., Cell cycle regulation in the inner ear sensory epithelia: role of cyclin D1 and cyclin-dependent kinase inhibitors. Dev Biol. Jan. 1, 2010;337(1):134-46. doi: 10.1016/j.ydbio.2009.10.027. Epub Oct. 23, 200… [cited by applicant]
Orthwein et al., A mechanism for the suppression of homologous recombination in G1 cells. Nature. Dec. 17, 2015;528(7582):422-6. doi: 10.1038/nature16142. Epub Dec. 9, 2015. Retraction in: Nature. Jan. 27, 2025. doi: 10… [cited by applicant]
Regalado et al., Some deaf children in China can hear after gene therapy treatment. MIT Technology Review. Oct. 27, 2023. Accessed online: https://www.technologyreview.com/2023/10/27/1082551/gene-treatment-deaf-children… [cited by applicant]
EP 21781660.2, dated Apr. 9, 2024, Extended European Search Report. [cited by applicant]